Meta analysis of randomized trials | Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer.

Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials – JAMA Oncology (free for a limited period)

Commentary on Twitter

In this meta-analysis of >11,000 patients with advanced gastroesophageal cancer, tissue PD-L1 expression — more than other variables besides microsatellite-high — identified varying degrees of benefit from immunotherapy-containing therapy. https://t.co/oUEDIEqLFj

— JAMA Oncology (@JAMAOnc) August 25, 2022